Mfn2 ubiquitination by PINK1/parkin gates the p97-dependent release of ER from mitochondria to drive mitophagy

  1. Gian-Luca McLelland
  2. Thomas Goiran
  3. Wei Yi
  4. Geneviève Dorval
  5. Carol X Chen
  6. Nadine D Lauinger
  7. Andrea I Krahn
  8. Sepideh Valimehr
  9. Aleksandar Rakovic
  10. Isabelle Rouiller
  11. Thomas M Durcan
  12. Jean-François Trempe
  13. Edward A Fon  Is a corresponding author
  1. Montreal Neurological Institute and Hospital, McGill University, Canada
  2. McGill University, Canada
  3. University of Lübeck, Germany

Abstract

Despite their importance as signaling hubs, the function of mitochondria-ER contact sites in mitochondrial quality control pathways remains unexplored. Here we describe a mechanism by which Mfn2, a mitochondria-ER tether, gates the autophagic turnover of mitochondria by PINK1 and parkin. Mitochondria-ER appositions are destroyed during mitophagy, and reducing mitochondria-ER contacts increases the rate of mitochondrial degradation. Mechanistically, parkin/PINK1 catalyze a rapid burst of Mfn2 phosphoubiquitination to trigger p97-dependent disassembly of Mfn2 complexes from the outer mitochondrial membrane, dissociating mitochondria from the ER. We additionally demonstrate that a major portion of the facilitatory effect of p97 on mitophagy is epistatic to Mfn2 and promotes the availability of other parkin substrates such as VDAC1. Finally, we reconstitute the action of these factors on Mfn2 and VDAC1 ubiquitination in a cell-free assay. We show that mitochondria-ER tethering suppresses mitophagy and describe a parkin-/PINK1-dependent mechanism that regulates the destruction of mitochondria-ER contact sites.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided for all Figures.

Article and author information

Author details

  1. Gian-Luca McLelland

    McGill Parkinson Program, Montreal Neurological Institute and Hospital, McGill University, Montreal, Canada
    Competing interests
    The authors declare that no competing interests exist.
  2. Thomas Goiran

    McGill Parkinson Program, Montreal Neurological Institute and Hospital, McGill University, Montreal, Canada
    Competing interests
    The authors declare that no competing interests exist.
  3. Wei Yi

    McGill Parkinson Program, Montreal Neurological Institute and Hospital, McGill University, Montreal, Canada
    Competing interests
    The authors declare that no competing interests exist.
  4. Geneviève Dorval

    McGill Parkinson Program, Montreal Neurological Institute and Hospital, McGill University, Montreal, Canada
    Competing interests
    The authors declare that no competing interests exist.
  5. Carol X Chen

    McGill Parkinson Program, Montreal Neurological Institute and Hospital, McGill University, Montreal, Canada
    Competing interests
    The authors declare that no competing interests exist.
  6. Nadine D Lauinger

    McGill Parkinson Program, Montreal Neurological Institute and Hospital, McGill University, Montreal, Canada
    Competing interests
    The authors declare that no competing interests exist.
  7. Andrea I Krahn

    McGill Parkinson Program, Montreal Neurological Institute and Hospital, McGill University, Montreal, Canada
    Competing interests
    The authors declare that no competing interests exist.
  8. Sepideh Valimehr

    Department of Anatomy and Cell Biology, McGill University, Montreal, Canada
    Competing interests
    The authors declare that no competing interests exist.
  9. Aleksandar Rakovic

    Institute of Neurogenetics, University of Lübeck, Lübeck, Germany
    Competing interests
    The authors declare that no competing interests exist.
  10. Isabelle Rouiller

    Department of Anatomy and Cell Biology, McGill University, Montreal, Canada
    Competing interests
    The authors declare that no competing interests exist.
  11. Thomas M Durcan

    McGill Parkinson Program, Montreal Neurological Institute and Hospital, McGill University, Montreal, Canada
    Competing interests
    The authors declare that no competing interests exist.
  12. Jean-François Trempe

    Department of Pharmacology and Therapeutics, McGill University, Montréal, Canada
    Competing interests
    The authors declare that no competing interests exist.
  13. Edward A Fon

    McGill Parkinson Program, Montreal Neurological Institute and Hospital, McGill University, Montreal, Canada
    For correspondence
    ted.fon@mcgill.ca
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5520-6239

Funding

Canadian Institutes of Health Research (Canada Graduate Scholarship)

  • Gian-Luca McLelland

Canadian Institutes of Health Research (Foundation Grant)

  • Edward A Fon

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2018, McLelland et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 9,748
    views
  • 1,991
    downloads
  • 277
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Gian-Luca McLelland
  2. Thomas Goiran
  3. Wei Yi
  4. Geneviève Dorval
  5. Carol X Chen
  6. Nadine D Lauinger
  7. Andrea I Krahn
  8. Sepideh Valimehr
  9. Aleksandar Rakovic
  10. Isabelle Rouiller
  11. Thomas M Durcan
  12. Jean-François Trempe
  13. Edward A Fon
(2018)
Mfn2 ubiquitination by PINK1/parkin gates the p97-dependent release of ER from mitochondria to drive mitophagy
eLife 7:e32866.
https://doi.org/10.7554/eLife.32866

Share this article

https://doi.org/10.7554/eLife.32866

Further reading

    1. Cell Biology
    Roberto Notario Manzano, Thibault Chaze ... Christel Brou
    Research Article

    Tunneling nanotubes (TNTs) are open actin- and membrane-based channels, connecting remote cells and allowing direct transfer of cellular material (e.g. vesicles, mRNAs, protein aggregates) from the cytoplasm to the cytoplasm. Although they are important especially, in pathological conditions (e.g. cancers, neurodegenerative diseases), their precise composition and their regulation were still poorly described. Here, using a biochemical approach allowing to separate TNTs from cell bodies and from extracellular vesicles and particles (EVPs), we obtained the full composition of TNTs compared to EVPs. We then focused on two major components of our proteomic data, the CD9 and CD81 tetraspanins, and further investigated their specific roles in TNT formation and function. We show that these two tetraspanins have distinct non-redundant functions: CD9 participates in stabilizing TNTs, whereas CD81 expression is required to allow the functional transfer of vesicles in the newly formed TNTs, possibly by regulating docking to or fusion with the opposing cell.

    1. Cell Biology
    Ming Zhang, Guangyi Du ... Wei Chen
    Research Article

    Noncoding RNA plays a pivotal role as novel regulators of endothelial cell function. Type 2 diabetes, acknowledged as a primary contributor to cardiovascular diseases, plays a vital role in vascular endothelial cell dysfunction due to induced abnormalities of glucolipid metabolism and oxidative stress. In this study, aberrant expression levels of circHMGCS1 and MIR4521 were observed in diabetes-induced human umbilical vein endothelial cell dysfunction. Persistent inhibition of MIR4521 accelerated development and exacerbated vascular endothelial dysfunction in diabetic mice. Mechanistically, circHMGCS1 upregulated arginase 1 by sponging MIR4521, leading to decrease in vascular nitric oxide secretion and inhibition of endothelial nitric oxide synthase activity, and an increase in the expression of adhesion molecules and generation of cellular reactive oxygen species, reduced vasodilation and accelerated the impairment of vascular endothelial function. Collectively, these findings illuminate the physiological role and interacting mechanisms of circHMGCS1 and MIR4521 in diabetes-induced cardiovascular diseases, suggesting that modulating the expression of circHMGCS1 and MIR4521 could serve as a potential strategy to prevent diabetes-associated cardiovascular diseases. Furthermore, our findings provide a novel technical avenue for unraveling ncRNAs regulatory roles of ncRNAs in diabetes and its associated complications.